AMLX stock forecast, quote, news & analysis
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs... Show more
Why Amylyx Pharmaceuticals (AMLX) Stock Is Up +66% in the Last 30 Days
Key Takeaways
- AMLX shares climbed roughly 66% over the last 30 days, rising from $20.31 to $33.75, driven by positive late-stage clinical data for its lead drug candidate, avexitide.
- On August 18, 2026, Amylyx reported that avexitide met its primary endpoint in the Phase 3 LUCIDITY trial, cutting severe hypoglycemic events by 55% versus placebo in post-bariatric hypoglycemia (PBH).
- Several analysts raised price targets following the data, including Guggenheim and H.C. Wainwright at $55, while the company priced an upsized $500 million stock offering.
- The stock is up roughly 140% over the last three months, extending a climb from about $14 in early June.
- Investors are now focused on the company's planned FDA New Drug Application (NDA) for avexitide, expected by the end of 2026.
Amylyx Pharmaceuticals (AMLX) Company Overview and Market Position
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing therapies for neurodegenerative and endocrine diseases. Its lead investigational asset is avexitide, a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist being developed for post-bariatric hypoglycemia (PBH), a rare condition that causes dangerously low blood sugar after weight-loss surgery.
The broader pipeline includes AMX0035 in Wolfram syndrome, AMX0114 (an antisense oligonucleotide targeting calpain-2) in amyotrophic lateral sclerosis (ALS), and AMX0318. Amylyx previously received U.S. approval for Relyvrio in ALS in 2022 but voluntarily withdrew the product in 2024 after its Phase 3 PHOENIX trial failed to meet its endpoint. The company currently has no marketed products, making avexitide's clinical progress central to its investment thesis.
Amylyx Pharmaceuticals (AMLX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AMLX rose from a closing price of $20.31 on July 31 to $33.75 on August 31, 2026, a gain of about 66%. The move was concentrated around August 18, when the stock surged roughly 63% in a single session to $35.11 after the LUCIDITY results were announced, reaching a 52-week high. The shares continued climbing to an intraday high near $41.13 on August 21 before settling back to $33.75 by month-end.
The longer-term trend is even stronger. Over the last three months, AMLX has more than doubled, rising from around $14 in early June to $33.75, a gain of roughly 140%. The quarterly move reflects a steady pre-data run-up through June and July, followed by the sharp re-rating after the August trial readout.
What Drove AMLX Stock Price in the Last 30 Days
The primary catalyst was the August 18 announcement of positive topline results from the Phase 3 LUCIDITY trial of avexitide in PBH. Amylyx reported that avexitide met its FDA-agreed primary endpoint, reducing the composite rate of Level 2 and Level 3 hypoglycemic events by 55% compared with placebo, while also meeting all secondary endpoints with a clean safety profile. PBH currently has no FDA-approved treatments, and avexitide already holds FDA Breakthrough Therapy and Orphan Drug designations.
The clinical win triggered a wave of analyst action. Guggenheim raised its price target from $40 to $55, H.C. Wainwright from $34 to $55, Robert W. Baird from $28 to $52, and Stifel from $21 to $45, with Wolfe Research upgrading the stock to Strong Buy. Amylyx also announced a $350 million public offering that was quickly upsized and priced at $500 million, signaling strong investor demand, and completed enrollment in the Phase 1 LUMINA trial of AMX0114.
What Drove AMLX Stock Performance Over the Last Quarter
Amylyx's quarterly rally was built on mounting anticipation ahead of the LUCIDITY data. The stock traded between roughly $13 and $24 through June and July as investors positioned for the pivotal readout. Second-quarter earnings reported on August 6 showed a net loss of $43.42 million, or $0.39 per share, slightly wider than consensus, but the market's focus remained on clinical catalysts rather than near-term financials.
The August 18 readout marked the inflection point, validating avexitide's lead position and shifting the narrative toward regulatory filing and potential commercialization. The $500 million financing, intended to fund pre-commercial activities and manufacturing capacity, reinforced the company's path toward a potential 2027 launch if approved.
Trending AI Robots
For traders seeking a data-driven approach to market moves like this one, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that trade thousands of tickers, but only the top-performing and most relevant bots appear in this section. These bots vary in strategy, timeframe, and performance metrics, giving users a range of approaches to evaluate. The page serves as a useful starting point for those interested in algorithmic trading tools and automated signal generation.
AMLX Stock Forecast Drivers: What Investors Should Watch Next
The next major milestone is Amylyx's planned NDA submission for avexitide in PBH by the end of 2026, followed by FDA review and a potential commercial launch. Investors will also watch for detailed LUCIDITY data presentations at medical meetings, updates on manufacturing and pre-commercial readiness funded by the recent offering, and progress across the pipeline, including AMX0035 in Wolfram syndrome and AMX0114 in ALS.
Key risks include the uncertainty of regulatory approval, commercialization execution in a competitive landscape, and the dilution from the recent share issuance. As a clinical-stage company with no current revenue, Amylyx remains dependent on clinical and regulatory outcomes to sustain its valuation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Aroon Indicator for AMLX shows an upward move is likely
AMLX's Aroon Indicator triggered a bullish signal on September 01, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 205 similar instances where the Aroon Indicator showed a similar pattern. In 188 of the 205 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMLX advanced for three days, in 232 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for AMLX moved out of overbought territory on August 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 22 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Momentum Indicator moved below the 0 level on September 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AMLX as a result. In 68 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for AMLX turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 36 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
AMLX broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AMLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.728) is normal, around the industry mean (46.728). P/E Ratio (2.686) is within average values for comparable stocks, (93.360). AMLX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.931). AMLX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (3.627) is also within normal values, averaging (176.516).
The Tickeron Profit vs. Risk Rating rating for this company is 66 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric